{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T20:45:16Z","timestamp":1770583516721,"version":"3.49.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Genetics"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.cancergen.2017.10.004","type":"journal-article","created":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T15:56:46Z","timestamp":1508774206000},"page":"13-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Myeloid neoplasm with eosinophilia associated with isolated extramedullary FIP1L1\/PDGFRA rearrangement"],"prefix":"10.1016","volume":"220","author":[{"given":"Talal","family":"Hilal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veena","family":"Fauble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhett P.","family":"Ketterling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katalin","family":"Kelemen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cancergen.2017.10.004_bib0010","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.cancergen.2017.10.004_bib0015","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.cancergen.2017.10.004_bib0020","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1182\/asheducation-2015.1.92","article-title":"Eosinophilia: a pragmatic approach to diagnosis and treatment","volume":"2015","author":"Klion","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.cancergen.2017.10.004_bib0025","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cancergen.2017.10.004_bib0030","first-page":"596","article-title":"The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1\/PDGFRA but not genomic rearrangements of other tyrosine kinases","volume":"90","author":"La Starza","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.cancergen.2017.10.004_bib0035","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood-2003-05-1627","article-title":"CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy","volume":"102","author":"Pardanani","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.cancergen.2017.10.004_bib0040","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/00000478-199310000-00006","article-title":"Extramedullary myeloid cell tumors. An immunohistochemical and morphologic study of 28 cases","volume":"17","author":"Traweek","year":"1993","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.cancergen.2017.10.004_bib0045","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1182\/blood-2006-10-050054","article-title":"Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia","volume":"109","author":"Jovanovic","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.cancergen.2017.10.004_bib0050","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/sj.leu.2403600","article-title":"Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia","volume":"19","author":"von Bubnoff","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergen.2017.10.004_bib0055","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood-2006-02-004457","article-title":"Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant","volume":"108","author":"Lierman","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cancergen.2017.10.004_bib0060","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.1182\/blood-2006-01-0285","article-title":"The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib)","volume":"107","author":"von Bubnoff","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cancergen.2017.10.004_bib0065","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/leu.2009.2","article-title":"FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib","volume":"23","author":"Lierman","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergen.2017.10.004_bib0070","doi-asserted-by":"crossref","first-page":"696","DOI":"10.3324\/haematol.2009.021675","article-title":"Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1","volume":"95","author":"Bain","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.cancergen.2017.10.004_bib0075","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.cancergen.2017.10.004_bib0080","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00277-015-2451-7","article-title":"Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene","volume":"94","author":"Rumi","year":"2015","journal-title":"Ann Hematol"}],"container-title":["Cancer Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210776217302776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210776217302776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:42:19Z","timestamp":1761896539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210776217302776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":15,"alternative-id":["S2210776217302776"],"URL":"https:\/\/doi.org\/10.1016\/j.cancergen.2017.10.004","relation":{},"ISSN":["2210-7762"],"issn-type":[{"value":"2210-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myeloid neoplasm with eosinophilia associated with isolated extramedullary FIP1L1\/PDGFRA rearrangement","name":"articletitle","label":"Article Title"},{"value":"Cancer Genetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cancergen.2017.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}